Author:
De Lazzari E,León A,Arnaiz JA,Martinez E,Knobel H,Negredo E,Clotet B,Montaner J,Storfer S,Asenjo MA,Mallolas J,Miró JM,Gatell JM
Subject
Pharmacology (medical),Infectious Diseases,Health Policy
Reference22 articles.
1. 1 US Food and Drug Administration Center for Drug Evaluation and Research. FDA public health advisory for nevirapine (Viramunetm) (19 January 2005). Efficacy and safety concerns regarding the coadministration of tenofovir disoproxil fumarate (TDF, Viread) and didanosine (ddI, Videx). EMEA Public Statement (EMEA/6231/2005). Available at: http://www.fda.gov/cder/drug/advisory/nevirapine.htm
2. 2 EMEA. No. II/0049, 16 March 2005.
3. A Comprehensive Hepatic Safety Analysis of Nevirapine in Different Populations of HIV Infected Patients*
4. The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART
5. 5 S Storfer, J Leith, P Robinson, P Piliero, and D. Hall Analysis of hepatic events within the 2NN study: controlling for geographic region and CD4+ cell count at initiation of nevirapine therapy.45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, December 2005 [LB-13].
Cited by
44 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献